AGTC is under the radar screen for most investors, evidently, even though there are two high-profile companies—AAVL and ONCE—with closely related pursuits. Gene-therapy market caps: https://twitter.com/bradloncar/status/561646087740862465/photo/1 Showing enterprise values (rather than market caps) would be more illuminating, but Brad’s chart gets the point across.